New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:18 EDTVRXValeant sees FY14 cash EPS $8.25-$8.75, consensus $8.75
Sees FY14 revenue $8.2B-$8.6B, consensus $8.29B. Sees FY14 adjusted cash flow from operations $2.4B-$2.6B. Guidance in slides for 2014 financial guidance conference call.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent VRX news | >>
November 18, 2014
06:49 EDTVRXValeant likely to pursue more moderate-sized deals, says Piper Jaffray
Subscribe for More Information
November 17, 2014
09:32 EDTVRXValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
06:05 EDTVRXActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
14:02 EDTVRXAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
09:38 EDTVRXJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
November 13, 2014
09:33 EDTVRXZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:23 EDTVRXValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
10:09 EDTVRXActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
06:22 EDTVRXZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
16:24 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
15:46 EDTVRXPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
08:32 EDTVRXValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
November 9, 2014
13:26 EDTVRXAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
November 7, 2014
17:05 EDTVRXValeant sends open letter to physician customers
Subscribe for More Information
14:56 EDTVRXAllergan says Valeant offers to date inadequate, would consider increased bid
Subscribe for More Information
09:49 EDTVRXAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
November 6, 2014
10:30 EDTVRXAllergan disclosure today forced by SEC, CNBC's Faber reports
Subscribe for More Information
09:28 EDTVRXActavis in active talks to acquire Allergan, Bloomberg reports
Actavis (ACT) is in active talks to acquire Allergan (AGN), Bloomberg reports, citing sources. Allergan earlier today disclosed in a filing that it has been approached by another party and that talks "may lead to negotiations." Shares of Allergan are up 1.1% to $198.50 in pre-open trading while Actavis is up 1% to $250.07. Valeant (VRX) is down 1.8% to $129.58. Reference Link
09:24 EDTVRXActavis in active talks to acquire Allergan, Bloomberg reports
Subscribe for More Information
09:06 EDTVRXAllergan says approach may lead to merger negotiations
Allergan (AGN) disclosed in new regulatory filing, “Notwithstanding the foregoing, we have been approached by another party regarding a potential merger transaction. Discussions between us and that party have continued and may lead to negotiations.” It has been reported that the unnamed party is Actavis (ACT). Allergan is attempting to fend off a hostile takeover by Valeant (VRX).
1 | 2 | all recent VRX news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use